Back Hepatitis B Hepatitis B Topics HBV Treatment

Heavy Alcohol Use Impairs Biochemical Response to Entecavir for Chronic Hepatitis B

While obese chronic hepatitis B patients and heavy drinkers did not have impaired virological response to entecavir (Baraclude), alcohol use did reduce the likelihood of alanine aminotransferase (ALT) normalization, according to study findings reported in the June 2012 issue of Clinical and Molecular Hepatology. alt

Read more:

Tenofovir Is Safe and Effective for Treating Hepatitis B in Adolescents

Teenagers with chronic hepatitis B virus (HBV) infection responded well to 2 years of treatment with tenofovir (Viread) in the first study of the drug in this population, researchers reported in the August 27, 2012, advance online edition of Hepatology.


Read more:

EASL Publishes Revised Clinical Practice Guidelines for Chronic Hepatitis B

The European Association for the Study of the Liver (EASL) recently revised its clinical practice guidelines for the management of patients with chronic hepatitis B virus (HBV) infection. The new recommendations were announced at the International Liver Congress in April in Barcelona and published in the July 2012 Journal of Hepatology. alt

Read more:

Tenofovir Hepatitis B Label Update Adds Info on Adolescents, Long-term Data for Adults

The U.S. Food and Drug Administration (FDA) this week announced that product label information for tenofovir (Viread) has been revised to include further information about treatment of chronic hepatitis B in teenagers and 240-week data for adult patients. alt

Read more:

EASL 2012: Telbivudine Effective for Hepatitis B Patients Selected with Roadmap

Telbivudine (Tyzeka) is an effective treatment for chronic hepatitis B with minimal emergence of drug resistance when using the "Roadmap" algorithm for selecting appropriate patients and deciding when to add other agents, according to a trio of studies presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.alt

Read more: